Clinical benefit with PEMAZYRE — 1 of 3

PEMAZYRE provides clinically meaningful responses

The efficacy of PEMAZYRE was investigated in the FIGHT–202 study in patients with previously treated CCA harbouring FGFR2 fusions or rearrangements (N=108)1

ORR1
(primary endpoint)

37

%

n=40

(95% CI, 27.94–46.86)

4 (3.7%)

patients had a confirmed CR1

36 (33.3%)

patients had a confirmed PR1

Median time to response1

2.7

MONTHS

(range, 0.7–6.9 months)

Median PFS1

7.0

MONTHS

(95% CI, 6.08–10.48)

Median OS1

17.5

MONTHS

(95% CI, 14.42–22.93)

For further efficacy information, please refer to the PEMAZYRE Swissmedic Professional Information.1